Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Retained Earnings: 2016-2024

Historic Retained Earnings for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Dec 2024 value amounting to -$1.2 billion.

  • Rocket Pharmaceuticals' Retained Earnings fell 20.69% to -$1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 billion, marking a year-over-year decrease of 20.69%. This contributed to the annual value of -$1.2 billion for FY2024, which is 26.97% down from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Retained Earnings of -$1.2 billion as of FY2024, which was down 26.97% from -$959.4 million recorded in FY2023.
  • In the past 5 years, Rocket Pharmaceuticals' Retained Earnings ranged from a high of -$322.8 million in FY2020 and a low of -$1.2 billion during FY2024.
  • Its 3-year average for Retained Earnings is -$963.8 million, with a median of -$959.4 million in 2023.
  • Data for Rocket Pharmaceuticals' Retained Earnings shows a maximum YoY crashed of 76.28% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Rocket Pharmaceuticals' Retained Earnings stood at -$322.8 million in 2020, then slumped by 52.37% to -$491.9 million in 2021, then crashed by 45.10% to -$713.8 million in 2022, then plummeted by 34.41% to -$959.4 million in 2023, then dropped by 26.97% to -$1.2 billion in 2024.